AR018376A1 - Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento - Google Patents
Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamentoInfo
- Publication number
- AR018376A1 AR018376A1 ARP990102454A ARP990102454A AR018376A1 AR 018376 A1 AR018376 A1 AR 018376A1 AR P990102454 A ARP990102454 A AR P990102454A AR P990102454 A ARP990102454 A AR P990102454A AR 018376 A1 AR018376 A1 AR 018376A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- pharmaceutical compositions
- dispersed
- same
- medicinal product
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000002269 spontaneous effect Effects 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000003890 substance P antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811200.6A GB9811200D0 (en) | 1998-05-26 | 1998-05-26 | Organic compounds |
| GBGB9818105.0A GB9818105D0 (en) | 1998-08-19 | 1998-08-19 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018376A1 true AR018376A1 (es) | 2001-11-14 |
Family
ID=26313736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102454A AR018376A1 (es) | 1998-05-26 | 1999-05-24 | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20020156099A1 (enExample) |
| EP (1) | EP1082119B1 (enExample) |
| JP (1) | JP4083985B2 (enExample) |
| KR (1) | KR20010043669A (enExample) |
| CN (1) | CN1270714C (enExample) |
| AR (1) | AR018376A1 (enExample) |
| AT (1) | ATE257380T1 (enExample) |
| AU (1) | AU755134B2 (enExample) |
| BE (1) | BE1012143A5 (enExample) |
| BR (1) | BR9910696A (enExample) |
| CA (1) | CA2333154C (enExample) |
| DE (2) | DE19983247T1 (enExample) |
| DK (1) | DK1082119T3 (enExample) |
| ES (1) | ES2214859T3 (enExample) |
| FR (1) | FR2779145B1 (enExample) |
| GB (1) | GB2353473A (enExample) |
| HU (1) | HUP0102202A3 (enExample) |
| ID (1) | ID27096A (enExample) |
| IL (1) | IL139501A0 (enExample) |
| IT (1) | IT1313551B1 (enExample) |
| NO (1) | NO20005920L (enExample) |
| NZ (1) | NZ508325A (enExample) |
| PE (1) | PE20000537A1 (enExample) |
| PL (1) | PL344245A1 (enExample) |
| PT (1) | PT1082119E (enExample) |
| RU (1) | RU2240121C2 (enExample) |
| SK (1) | SK17752000A3 (enExample) |
| TR (1) | TR200003502T2 (enExample) |
| TW (1) | TW537894B (enExample) |
| WO (1) | WO1999061025A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW537894B (en) | 1998-05-26 | 2003-06-21 | Novartis Ag | A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist |
| US7202282B2 (en) * | 2002-04-22 | 2007-04-10 | University Of Florida | Microemulsions for selective molecular separation |
| GB0220953D0 (en) | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
| US7842791B2 (en) | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| FR2934953B1 (fr) | 2008-08-14 | 2011-01-21 | Commissariat Energie Atomique | Nanoemulsions de nanocristaux |
| FR2934954B1 (fr) | 2008-08-14 | 2011-07-22 | Commissariat Energie Atomique | Emulsion fluorescente de vert d'indocyanine |
| FR2934955B1 (fr) | 2008-08-14 | 2011-07-08 | Commissariat Energie Atomique | Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions |
| FR2935001B1 (fr) * | 2008-08-14 | 2011-12-30 | Commissariat Energie Atomique | Emulsion fluorescente |
| ES2969933T3 (es) | 2012-12-31 | 2024-05-23 | Jrx Biotechnology Inc | Formulaciones farmacéuticas tópicas líquidas en nanoemulsión |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3305689A1 (de) | 1983-02-18 | 1984-08-23 | Mack Chem Pharm | Pharmazeutische zubereitung mit retardwirkung |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| DE4220616C2 (de) | 1992-06-24 | 1994-12-22 | Byk Gulden Lomberg Chem Fab | Dexniguldipin zur intravenösen Verabreichung |
| PT589843E (pt) | 1992-09-25 | 2002-04-29 | Novartis Ag | Composicoes farmaceuticas contendo ciclosporinas |
| GB2278780B (en) * | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| AU696855B2 (en) * | 1994-03-18 | 1998-09-17 | Shire Laboratories, Inc. | Emulsified drug delivery systems |
| TW397825B (en) * | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
| GB2308545B (en) | 1994-10-26 | 1999-06-02 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| MY129435A (en) * | 1994-10-26 | 2007-04-30 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| FR2728165A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
| FR2728169A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
| DE69617226T2 (de) * | 1995-03-27 | 2002-07-25 | Hisamitsu Pharmaceutical Co., Inc. | Piperidinderivate. |
| NZ280689A (en) | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| AU2898297A (en) | 1996-05-24 | 1998-01-05 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| TW537894B (en) | 1998-05-26 | 2003-06-21 | Novartis Ag | A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist |
-
1999
- 1999-05-24 TW TW088108449A patent/TW537894B/zh not_active IP Right Cessation
- 1999-05-24 AR ARP990102454A patent/AR018376A1/es not_active Application Discontinuation
- 1999-05-25 PE PE1999000436A patent/PE20000537A1/es not_active Application Discontinuation
- 1999-05-25 BE BE9900364A patent/BE1012143A5/fr not_active IP Right Cessation
- 1999-05-26 KR KR1020007012871A patent/KR20010043669A/ko not_active Ceased
- 1999-05-26 JP JP2000550485A patent/JP4083985B2/ja not_active Expired - Fee Related
- 1999-05-26 PL PL99344245A patent/PL344245A1/xx unknown
- 1999-05-26 GB GB0028506A patent/GB2353473A/en not_active Withdrawn
- 1999-05-26 IT IT1999MI001164A patent/IT1313551B1/it active
- 1999-05-26 AU AU45008/99A patent/AU755134B2/en not_active Ceased
- 1999-05-26 DE DE19983247T patent/DE19983247T1/de not_active Withdrawn
- 1999-05-26 BR BR9910696-5A patent/BR9910696A/pt not_active Application Discontinuation
- 1999-05-26 HU HU0102202A patent/HUP0102202A3/hu unknown
- 1999-05-26 NZ NZ508325A patent/NZ508325A/xx unknown
- 1999-05-26 CN CNB998066036A patent/CN1270714C/zh not_active Expired - Fee Related
- 1999-05-26 EP EP99927760A patent/EP1082119B1/en not_active Expired - Lifetime
- 1999-05-26 ID IDW20002316A patent/ID27096A/id unknown
- 1999-05-26 WO PCT/EP1999/003623 patent/WO1999061025A1/en not_active Ceased
- 1999-05-26 IL IL13950199A patent/IL139501A0/xx unknown
- 1999-05-26 ES ES99927760T patent/ES2214859T3/es not_active Expired - Lifetime
- 1999-05-26 SK SK1775-2000A patent/SK17752000A3/sk unknown
- 1999-05-26 FR FR9906629A patent/FR2779145B1/fr not_active Expired - Fee Related
- 1999-05-26 DK DK99927760T patent/DK1082119T3/da active
- 1999-05-26 TR TR2000/03502T patent/TR200003502T2/xx unknown
- 1999-05-26 CA CA002333154A patent/CA2333154C/en not_active Expired - Fee Related
- 1999-05-26 RU RU2000133308/15A patent/RU2240121C2/ru not_active IP Right Cessation
- 1999-05-26 DE DE69914077T patent/DE69914077T2/de not_active Expired - Lifetime
- 1999-05-26 AT AT99927760T patent/ATE257380T1/de not_active IP Right Cessation
- 1999-05-26 PT PT99927760T patent/PT1082119E/pt unknown
-
2000
- 2000-11-23 NO NO20005920A patent/NO20005920L/no not_active Application Discontinuation
-
2002
- 2002-04-10 US US10/119,549 patent/US20020156099A1/en not_active Abandoned
-
2003
- 2003-03-04 US US10/379,345 patent/US6949257B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| AR015820A1 (es) | Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| AR032132A1 (es) | Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento | |
| AR033367A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos | |
| PT1119543E (pt) | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y | |
| GEP20063741B (en) | Nonaryl-Heterocyclic NMDA/NR2B Antagonists | |
| BRPI0410721A (pt) | composições farmacêuticas espumáveis e métodos para tratamento de um distúrbio | |
| MX9301348A (es) | Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende. | |
| DE60318237D1 (de) | Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol | |
| ECSP034438A (es) | Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c | |
| BR122018003623B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
| AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
| UY27993A1 (es) | Derivados de 4-pirrolidino-fenil-bencil eter | |
| BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
| ES2167401T3 (es) | Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias. | |
| AR018376A1 (es) | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento | |
| BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
| PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
| CO5200850A1 (es) | Composicion farmaceutica para profilaxis y tratamiento de sintomas asociados con la gripa, influenza y enfermedades similares y procedimiento para su aplicacion | |
| AR008903A1 (es) | Piperazino derivados como antagonistas de neurokinina, una composicion farmaceutica que comprende dichos compuestos de formula (i), un procedimientopara la preparacion de dicha composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento | |
| BRPI0408113A (pt) | métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica | |
| SE0103210D0 (sv) | New formulations and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FA | Abandonment or withdrawal |